Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps
About the study
This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Adults aged ≥18 years
- Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS)
- Patients prescribed with Xolair® as per the locally approved label information.
- Patients who provide written informed consent to participate in the study
EXCLUSION CRITERIA
Exclusion Criteria:
- Patients who do not provide consent to participate in the study
- Patients participating in other clinical trial
- Contraindications listed in the locally approved label information of Xolair®
- Hypersensitivity to the active ingredient or any other ingredient of Xolair®
- Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Chronic Rhinosinusitis With Nasal Polyps
Age
18 - 100
Participants Needed
112
Est. Completion Date
Jan 31, 2025
Treatment Type
OBSERVATIONAL
Sponsor
Novartis
ClinicalTrials.gov NCT Identifier
NCT05626257
Study Number
CIGE025EKR04
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?